These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 9806009)
1. [Recommendations for the study of drug combination therapy for the treatment of AIDS and cancer. Round Table No 7 at Giens XIII]. Armand JP; Dormont J; Schwebig A Therapie; 1998; 53(4):385-9. PubMed ID: 9806009 [TBL] [Abstract][Full Text] [Related]
2. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)]. Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725 [TBL] [Abstract][Full Text] [Related]
3. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. Gupta SB; Pujari SN; Joshi SR; Patel AK; J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742 [TBL] [Abstract][Full Text] [Related]
4. [Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)]. Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Antonio Iribarren J; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P; Enferm Infecc Microbiol Clin; 2000 Oct; 18(8):396-412. PubMed ID: 11153204 [TBL] [Abstract][Full Text] [Related]
5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
6. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR]. Haie-Meder C; Fervers B; Chauvergne J; Fondrinier E; Lhommé C; Guastalla JP; Resbeut M Bull Cancer; 1999 Oct; 86(10):829-41. PubMed ID: 10572234 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
14. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I; J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661 [TBL] [Abstract][Full Text] [Related]
15. New trial proposed for when drugs fail. James JS AIDS Treat News; 1995 May; (no 223):1-4. PubMed ID: 11362467 [TBL] [Abstract][Full Text] [Related]
18. Clinical news from the XVI International AIDS Conference: The attempt of a summing up. Jülg B; Goebel FD Infection; 2006 Oct; 34(5):294-7. PubMed ID: 17033758 [TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
20. A clinical development paradigm for cancer vaccines and related biologics. Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G; J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]